<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Genet</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-8021</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8784420</article-id>
    <article-id pub-id-type="publisher-id">792541</article-id>
    <article-id pub-id-type="doi">10.3389/fgene.2021.792541</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Genetics</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ImReLnc: Identifying Immune-Related LncRNA Characteristics in Human Cancers Based on Heuristic Correlation Optimization</article-title>
      <alt-title alt-title-type="left-running-head">Gao et al.</alt-title>
      <alt-title alt-title-type="right-running-head">Identifying Immune-Related lncRNA Characteristics</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gao</surname>
          <given-names>Meihong</given-names>
        </name>
        <uri xlink:href="https://loop.frontiersin.org/people/1120715/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Shuhui</given-names>
        </name>
        <uri xlink:href="https://loop.frontiersin.org/people/1212310/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qi</surname>
          <given-names>Yang</given-names>
        </name>
        <uri xlink:href="https://loop.frontiersin.org/people/1560083/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Xinpeng</given-names>
        </name>
        <uri xlink:href="https://loop.frontiersin.org/people/1226657/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shang</surname>
          <given-names>Xuequn</given-names>
        </name>
        <xref rid="c001" ref-type="corresp">*</xref>
        <uri xlink:href="https://loop.frontiersin.org/people/898708/overview"/>
      </contrib>
    </contrib-group>
    <aff><institution>School of Computer Science and Engineering, Northwestern Polytechnical University</institution>, <addr-line>Xi’an</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p><bold>Edited by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/142613/overview" ext-link-type="uri">Hongmin Cai</ext-link>, South China University of Technology, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p><bold>Reviewed by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/1041828/overview" ext-link-type="uri">Ehsan Nazemalhosseini-Mojarad</ext-link>, Shahid Beheshti University of Medical Sciences, Iran</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/359081/overview" ext-link-type="uri">Sohini Chakraborty</ext-link>, NYU Grossman School of Medicine, United States</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/775059/overview" ext-link-type="uri">Cheng Liang</ext-link>, Shandong Normal University, China</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/542575/overview" ext-link-type="uri">Qinghua Jiang</ext-link>, Harbin Institute of Technology, China</p>
      </fn>
      <corresp id="c001">*Correspondence: Xuequn Shang, <email>shang@nwpu.edu.cn</email>
</corresp>
      <fn fn-type="other">
        <p>This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>10</day>
      <month>1</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>792541</elocation-id>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>12</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Gao, Liu, Qi, Guo and Shang.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Gao, Liu, Qi, Guo and Shang</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Long non-coding RNAs (lncRNAs) play critical roles in cancer through gene expression and immune regulation. Identifying immune-related lncRNA (irlncRNA) characteristics would contribute to dissecting the mechanism of cancer pathogenesis. Some computational methods have been proposed to identify irlncRNA characteristics in human cancers, but most of them are aimed at identifying irlncRNA characteristics in specific cancer. Here, we proposed a new method, ImReLnc, to recognize irlncRNA characteristics for 33 human cancers and predict the pathogenicity levels of these irlncRNAs across cancer types. We first calculated the heuristic correlation coefficient between lncRNAs and mRNAs for immune-related enrichment analysis. Especially, we analyzed the relationship between lncRNAs and 17 immune-related pathways in 33 cancers to recognize the irlncRNA characteristics of each cancer. Then, we calculated the Pscore of the irlncRNA characteristics to evaluate their pathogenicity levels. The results showed that highly pathogenic irlncRNAs appeared in a higher proportion of known disease databases and had a significant prognostic effect on cancer. In addition, it was found that the expression of irlncRNAs in immune cells was higher than that of non-irlncRNAs, and the proportion of irlncRNAs related to the levels of immune infiltration was much higher than that of non-irlncRNAs. Overall, ImReLnc accurately identified the irlncRNA characteristics in multiple cancers based on the heuristic correlation coefficient. More importantly, ImReLnc effectively evaluated the pathogenicity levels of irlncRNAs across cancer types. ImReLnc is freely available at <ext-link xlink:href="https://github.com/meihonggao/ImReLnc" ext-link-type="uri">https://github.com/meihonggao/ImReLnc</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>immune-related lncRNA</kwd>
      <kwd>pathogenicity levels</kwd>
      <kwd>heuristic correlation coefficient</kwd>
      <kwd>enrichment analysis</kwd>
      <kwd>immune infiltration</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>1 Introduction</title>
    <p>Cancer is a major threat to human health with high incidence and mortality (<xref rid="B53" ref-type="bibr">Siegel et al., 2015</xref>; <xref rid="B9" ref-type="bibr">Bray et al., 2018</xref>; <xref rid="B15" ref-type="bibr">Ferlay et al., 2019</xref>; <xref rid="B22" ref-type="bibr">Gharib et al., 2019</xref>). In 2018, there were approximately 18.1 million new cases and 9.6 million cancer deaths worldwide (<xref rid="B9" ref-type="bibr">Bray et al., 2018</xref>; <xref rid="B15" ref-type="bibr">Ferlay et al., 2019</xref>). Although early detection and treatment of cancer have increased the number of survivors, the results are still limited (<xref rid="B40" ref-type="bibr">Miller et al., 2016</xref>, <xref rid="B39" ref-type="bibr">2019</xref>). Previous studies have reported that there is a link between lncRNA and the occurrence of cancer, and lncRNA plays an important role in cancer by gene expression and immune regulation (<xref rid="B23" ref-type="bibr">Gibb et al., 2011</xref>; <xref rid="B61" ref-type="bibr">Yang et al., 2014</xref>; <xref rid="B30" ref-type="bibr">Jiang et al., 2017</xref>; <xref rid="B36" ref-type="bibr">Li et al., 2020</xref>; <xref rid="B19" ref-type="bibr">Gao et al., 2021</xref>). The exploration of the lncRNA regulation mechanism is of great significance to the diagnosis and treatment of cancer (<xref rid="B7" ref-type="bibr">Bhan et al., 2017</xref>; <xref rid="B22" ref-type="bibr">Gharib et al., 2019</xref>, <xref rid="B21" ref-type="bibr">2021</xref>).</p>
    <p>Long non-coding RNA (lncRNA) refers to a transcript located in the nucleus or cytoplasm and is more than 200 nucleotides in length and cannot encode protein. (<xref rid="B59" ref-type="bibr">Wang and Chang, 2011</xref>; <xref rid="B49" ref-type="bibr">Ransohoff et al., 2018</xref>; <xref rid="B41" ref-type="bibr">Nair et al., 2020</xref>). With the development of sequencing technology, more and more lncRNAs have been identified and annotated (<xref rid="B67" ref-type="bibr">Zhao et al., 2016</xref>; <xref rid="B17" ref-type="bibr">Frankish et al., 2021</xref>). Studies have shown that lncRNA is related to the occurrence of cancer and participates in cell life activities through epigenetic modification, transcriptional regulation, post-transcriptional processing, and translational regulation (<xref rid="B14" ref-type="bibr">Esteller, 2011</xref>; <xref rid="B4" ref-type="bibr">Bao et al., 2019</xref>; <xref rid="B11" ref-type="bibr">Chi et al., 2019</xref>; <xref rid="B66" ref-type="bibr">Zhao et al., 2020</xref>). For example, GATA6-AS epigenetically regulates endothelial gene expression by interacting with LOXL2 (<xref rid="B43" ref-type="bibr">Neumann et al., 2018</xref>), CCR5AS regulates the expression of CCR5 to affect the outcome of HIV infection (<xref rid="B33" ref-type="bibr">Kulkarni et al., 2019</xref>), and OIS1 regulates the activation of DPP4 to control RAS-induced senescence (<xref rid="B35" ref-type="bibr">Li et al., 2018</xref>). In addition, lncRNA is involved in various processes of immune response in the tumor microenvironment (TME) and plays an important immunomodulatory role in cancer. It is reported that lncRNA NKILA promotes tumor immune escape by sensitizing T cells to activation-induced cell death (<xref rid="B28" ref-type="bibr">Huang et al., 2018</xref>) and lncRNA HOTAIR regulates the expression of the glucose transporter Glut1 and glucose uptake in macrophages during inflammation (<xref rid="B45" ref-type="bibr">Obaid et al., 2021</xref>).</p>
    <p>TME is a complex environment around tumors and is crucial for tumor growth, invasion, and metastasis (<xref rid="B48" ref-type="bibr">Quail and Joyce, 2013</xref>; <xref rid="B62" ref-type="bibr">Yuan et al., 2016</xref>). The composition of TME varies by tumor type, but hallmark features include immune cells, stromal cells, blood vessels, and extracellular matrix (<xref rid="B31" ref-type="bibr">Joyce and Fearon, 2015</xref>; <xref rid="B54" ref-type="bibr">Spill et al., 2016</xref>; <xref rid="B1" ref-type="bibr">Anderson and Simon, 2020</xref>). There is a close interaction between tumor cells and their surrounding TME, and the phenomenon of other cells entering the tumor tissue is called infiltration (<xref rid="B18" ref-type="bibr">Fridman et al., 2011</xref>). The infiltration of immune cells in tumor tissue significantly impacts tumor proliferation and metastasis. Lymphocytes that infiltrate tumor tissues are called tumor-infiltrating lymphocytes, which include T cells and B cells and are part of the larger category of tumor-infiltrating immune cells (<xref rid="B18" ref-type="bibr">Fridman et al., 2011</xref>; <xref rid="B42" ref-type="bibr">Nazemalhosseini-Mojarad et al., 2019</xref>). The abundance of tumor-infiltrating lymphocytes varies with tumor type and stage and is related to the prognosis of the disease in some cases (<xref rid="B18" ref-type="bibr">Fridman et al., 2011</xref>; <xref rid="B25" ref-type="bibr">Hanahan and Coussens, 2012</xref>; <xref rid="B12" ref-type="bibr">Coussens et al., 2013</xref>). Tumor-infiltrating lymphocytes can usually be found in tumor stroma and tumor itself, where they can help tumor cells escape and promote the development of malignant tumors. LncRNAs participate in tumor-stroma crosstalk and stimulate a distinctive and suitable tumor microenvironment (<xref rid="B55" ref-type="bibr">Sun et al., 2020</xref>; <xref rid="B68" ref-type="bibr">Zhou et al., 2020</xref>). Thus, it is necessary to identify immune-related lncRNA (irlncRNA) to explore the immune regulation mechanism of lncRNA in tumors.</p>
    <p>Identifying irlncRNA helps us understand the mechanism of cancer at the molecular level, contributing to the diagnosis and treatment of cancer. However, due to lncRNA’s specific expression, its pathogenicity level across cancer types is difficult to estimate. The development of computational methods for identifying irlncRNA in cancer and assessing its pathogenicity can help solve this problem. Several methods have been proposed to identify irlncRNAs for human cancers (<xref rid="B52" ref-type="bibr">Shen et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Sun et al., 2020</xref>; <xref rid="B65" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B19" ref-type="bibr">Gao et al., 2021</xref>), but the common goal of these methods is to identify irlncRNAs associated with single cancer. There is only one method named ImmLnc that can identify irlncRNAs for multiple cancers (<xref rid="B36" ref-type="bibr">Li et al., 2020</xref>). ImmLnc has a good performance on the given cancer dataset, but it has two limitations that need to be improved. On the one hand, ImmLnc uses partial correlation to calculate the ranking score, but direct correlation and partial correlation coexist in cancer tissues. On the other hand, ImmLnc uses the number of cancers in which irlncRNA-pathway pair is involved and the number of cancers in which irlncRNA is differentially expressed to calculate the pathogenicity level of irlncRNA, but other factors may also affect the pathogenicity level of irlncRNA. Therefore, it is necessary to integrate direct correlation and partial correlation to identify irlncRNA for human cancers and consider adding other factors to evaluate the pathogenic level of irlncRNA effectively.</p>
    <p>Here, we proposed a new method ImReLnc for two main objectives. Firstly, we used heuristic correlation coefficients to provide ranking scores for immune-related enrichment analysis to identify irlncRNAs in human cancers. Especially, we integrated direct correlation coefficients and partial correlation coefficients based on the logistic function to obtain the heuristic correlation coefficients. We identified the irlncRNAs of 33 cancers and found that these irlncRNAs were highly expressed in immune cells, showed expression differences in cancers, and were significantly related to immune infiltration levels. The second goal of this method is to evaluate the pathogenicity levels of the identified irlncRNAs. For each irlncRNA identified by ImReLnc, we calculated not only the number of cancers in which lncRNA-pathway pair was involved but also the number of cancers in which irlncRNA was differentially expressed and its average fold change in those differentially expressed cancers. By comparing irlncRNAs with disease-related lncRNAs (drlncRNAs) in LncRNADisease2.0 (<xref rid="B3" ref-type="bibr">Bao et al., 2018</xref>) and Lnc2Cancer2.0 (<xref rid="B20" ref-type="bibr">Gao et al., 2018</xref>), we found that highly pathogenic irlncRNAs appeared in a higher proportion of known disease database than low pathogenic irlncRNAs. This demonstrates that ImReLnc is a valuable resource for predicting the pathogenicity of irlncRNA in human cancers.</p>
  </sec>
  <sec sec-type="materials|methods" id="s2">
    <title>2 Materials and Methods</title>
    <p><xref rid="F1" ref-type="fig">Figure 1</xref> shows the framework of ImReLnc for identifying irlncRNAs and evaluating their pathogenicity levels.</p>
    <fig position="float" id="F1">
      <label>FIGURE 1</label>
      <caption>
        <p>The flowchart of ImReLnc. The expression matrix in step 1 refers to the normalized expression profile of 33 cancers. The correlation in step 2 refers to the correlation between mRNA and lncRNA.</p>
      </caption>
      <graphic xlink:href="fgene-12-792541-g001" position="float"/>
    </fig>
    <sec id="s2-1">
      <title>2.1 Data Acquisition and Processing</title>
      <sec id="s2-1-1">
        <title>2.1.1 Expression Data Collection</title>
        <p>The expression profiles of 33 types of cancer were downloaded from TCGA (See <xref rid="s10" ref-type="sec">Supplementary Table S1</xref>, Data Sheet 1). For each type of cancer, we used Perl to process the expression profiles of all samples into an expression matrix, which was filtered by the annotation file in GENECODE (v22) to obtain the expression matrix of mRNA and lncRNA.</p>
        <p>Hepatic carcinoma-related single-cell sequencing data was downloaded from Panglaodb. We performed cluster analysis on single-cell sequencing data to obtain the expression matrix of immune and non-immune cells through the Seurat package in R software. We further analyzed the expression matrix of lncRNA in these two types of cells and obtained the expression matrix of irlncRNA and non-irlncRNA in them.</p>
      </sec>
      <sec id="s2-1-2">
        <title>2.1.2 Immunization Data Collection</title>
        <p>Immune-related gene lists were downloaded from Immport, which is one of the largest public databases for collecting and sharing immunology-related research resources. A total of 17 immune pathways and 1793 immune-related mRNAs were obtained for immune-related enrichment analysis, and the number of mRNAs associated with immune pathways ranged from 3 to 505 (See <xref rid="s10" ref-type="sec">Supplementary Table S2</xref>, Data Sheet 1).</p>
        <p>The immune infiltration levels of TCGA cancer samples (33 types of cancer samples) were downloaded from Timer. We obtained the infiltration levels of these cancer samples in six types of cells: B cell, T cell CD4<sup>+</sup>, T cell CD8<sup>+</sup>, Neutrophil, Macrophage, and Myeloid dendritic cell.</p>
      </sec>
      <sec id="s2-1-3">
        <title>2.1.3 LncRNA-Disease Interactions Collection</title>
        <p>We collected the human lncRNA–disease interactions from LncRNADisease and Lnc2Cancer. Specifically, 2665 drlncRNAs were collected from Lnc2Cancer, and 6,105 drlncRNAs were collected from Lnc2Cancer. After preprocessing (removal of duplicate items), there were 2665 drlncRNAs left in Lnc2Cancer and 5,714 drlncRNAs left in LncRNADisease.</p>
      </sec>
    </sec>
    <sec id="s2-2">
      <title>2.2 Heuristic Correlation Optimization</title>
      <p>LncRNA can regulate the expression of mRNA to cause cancer, and there are two regulatory patterns: direct regulation and indirect regulation (<xref rid="F2" ref-type="fig">Figure 2</xref>). In the first pattern, the expression values of lncRNA and mRNAlncRNA and mRNA expression values are directly related, while in the second pattern, they are partially related.</p>
      <fig position="float" id="F2">
        <label>FIGURE 2</label>
        <caption>
          <p>Direct correlation and Partial correlation. Here, m, l, t represents mRNA, lncRNA, tumor purity, respectively.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g002" position="float"/>
      </fig>
      <sec id="s2-2-1">
        <title>2.2.1 Direct Correlation Between mRNAs and lncRNAs</title>
        <p>The direct correlation was computed through the method of Pearson and Spearman (<xref rid="B6" ref-type="bibr">Benesty et al., 2009</xref>; <xref rid="B51" ref-type="bibr">Sedgwick, 2014</xref>). The Pearson’s rank correlation coefficient between mRNA <italic>m</italic> and lncRNA <italic>l</italic> is defined as follows:<disp-formula id="e1"><mml:math id="m1" overflow="scroll"><mml:mi>R</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mfenced><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:msup><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:msqrt><mml:mrow><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:msup><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:math><label>(1)</label></disp-formula>where function <italic>E</italic> is used to calculate the mathematical expectation of variables. Similarly, the Spearman’s correlation coefficient between mRNA <italic>m</italic> and lncRNA <italic>l</italic> is defined as follows:<disp-formula id="e2"><mml:math id="m2" overflow="scroll"><mml:mi>S</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>6</mml:mn><mml:mo>∑</mml:mo><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:munderover></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:msup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math><label>(2)</label></disp-formula>where <italic>d</italic>
<sub><italic>i</italic></sub> represents the difference between the rank of <italic>m</italic> and <italic>l</italic>, and <italic>r</italic> represents the number of cancer samples. Although Pearson correlation and Spearman correlation can effectively fit the correlation between mRNA and lncRNA in cancer samples, they have some limitations. To make the value of direct correlation more accurate, we combined these two types of correlation coefficients to represent the direct correlation coefficient as follows:<disp-formula id="e3"><mml:math id="m3" overflow="scroll"><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:math><label>(3)</label></disp-formula>
</p>
      </sec>
      <sec id="s2-2-2">
        <title>2.2.2 Partial Correlation Between mRNAs and lncRNAs</title>
        <p>Tumor purity affects the expression of mRNA and lncRNA in cancer samples. To eliminate this effect, we calculated the partial correlation between mRNA and lncRNA based on tumor purity. The tumor purity of the sample was calculated by analyzing its mRNA expression profile using the estimate package of R software. The partial correlation coefficient between mRNA <italic>m</italic> and lncRNA <italic>l</italic> in sample <italic>t</italic> is defined as follows:<disp-formula id="e4"><mml:math id="m4" overflow="scroll"><mml:mi>P</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>−</mml:mo><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:math><label>(4)</label></disp-formula>
</p>
      </sec>
      <sec id="s2-2-3">
        <title>2.2.3 Heuristic Correlation Between mRNAs and lncRNAs</title>
        <p>Both direct and partial correlations play an important role in lncRNA regulating mRNA expression. Thus, we integrated these two correlations to calculate the heuristic correlation between mRNA and lncRNA. To highlight the strong correlation and to fade the weak correlation, we defined a logistic function as follows:<disp-formula id="e5"><mml:math id="m5" overflow="scroll"><mml:mi>L</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>x</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:math><label>(5)</label></disp-formula>where <italic>x</italic> is the absolute value of the correlation coefficient. When <italic>c</italic> is equal to -15 and <italic>d</italic> is equal to ln (1999), <italic>L</italic>(<italic>x</italic>) is approximately equal to 0 in the interval [0, 0.3], and <italic>L</italic>(<italic>x</italic>) is approximately equal to 1 in the interval [0, 0.7] (See <xref rid="s10" ref-type="sec">Supplementary Figure S1</xref>, Data Sheet 1). Furthermore, we define the heuristic correlation coefficient between mRNA m and lncRNA l as follows:<disp-formula id="e6"><mml:math id="m6" overflow="scroll"><mml:mtable class="matrix"><mml:mtr><mml:mtd columnalign="center"><mml:mi>H</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>L</mml:mi><mml:mfenced open="[" close="]"><mml:mrow><mml:mi>β</mml:mi><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:mfenced><mml:mi>P</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mtd></mml:mtr></mml:mtable></mml:math><label>(6)</label></disp-formula>where <italic>β</italic> ranges from 0 to 1 and is limitid as follows:<disp-formula id="e7"><mml:math id="m7" overflow="scroll"><mml:munder><mml:mrow><mml:mi>arg min</mml:mi></mml:mrow><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:munder><mml:mfenced open="{" close="}"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:mi>β</mml:mi><mml:mi>D</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:mfenced><mml:mi>P</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mfenced></mml:math><label>(7)</label></disp-formula>
</p>
      </sec>
    </sec>
    <sec id="s2-3">
      <title>2.3 Identification of Immune-Related lncRNAs</title>
      <sec id="s2-3-1">
        <title>2.3.1 Immune-Related Enrichment Analysis</title>
        <p>The immune regulation mechanism of lncRNA was explored by analyzing the relationship between lncRNA-related mRNA and immune pathways. First, we performed a screening on the heuristic correlation matrix to obtain the rank matrix <italic>R</italic>
<sub><italic>ML</italic></sub> (the filtering threshold is 0.5). As a result, <italic>v</italic> lncRNA-related mRNA classes were obtained. Each class was composed of heuristic correlation coefficients between a lncRNA and the corresponding <italic>u</italic> mRNAs and was sorted in descending order according to these coefficients. Then we conducted enrichment analysis for the lncRNA-related mRNA classes on 17 immune pathways using fgsea package in R software. The minimum and maximum sizes of the mRNA class were set to 1 and 5,000, respectively, and the number of permutations was set to 10 000. The enrichment analysis result was a 17<italic>v</italic> × 10 matrix, whose column information includes lncRNA, immune pathway, <italic>p</italic>-value, adjusted <italic>p</italic>-value, enrichment score, and five other enrichment parameters.</p>
      </sec>
      <sec id="s2-3-2">
        <title>2.3.2 Extraction of Immune-Related lncRNAs</title>
        <p>We evaluated the relationship between lncRNA and immune pathway based on the enrichment score and <italic>p</italic> value as follows (<xref rid="B36" ref-type="bibr">Li et al., 2020</xref>):<disp-formula id="e8"><mml:math id="m8" overflow="scroll"><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>R</mml:mi><mml:mi>E</mml:mi><mml:mi>S</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced open="{" close=""><mml:mrow><mml:mtable class="cases"><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mspace width="1em"/></mml:mtd><mml:mtd columnalign="left"><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mfenced><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>2</mml:mn><mml:mi>p</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/></mml:mtd><mml:mtd columnalign="left"><mml:mi>E</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mfenced><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><label>(8)</label></disp-formula>where <italic>p</italic> represents the <italic>p</italic>-value of the enrichment result, and <italic>E</italic> (<italic>l</italic>, <italic>w</italic>) represents the enrichment score of lncRNA <italic>l</italic> on pathway <italic>w</italic>. Obviously, the range of <italic>lncRES</italic> (<italic>l</italic>, <italic>w</italic>) is [ − 1, 1], and the greater the absolute value, the higher the enrichment degree. For each type of cancer <italic>c</italic>, |<italic>I</italic>
<sub><italic>c</italic></sub>| irlncRNAs were obtained by setting the absolute value of <italic>lncRES</italic> (<italic>l</italic>, <italic>w</italic>) to be greater than 0.995 and setting the FDR to be less than 0.05. Finally, the set of all irlncRNAs in 33 types of cancer can be defined as follows:<disp-formula id="e9"><mml:math id="m9" overflow="scroll"><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mo>⋃</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>33</mml:mo></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math><label>(9)</label></disp-formula>Each irlncRNA in set <italic>I</italic> has several corresponding immune pathways to form lncRNA-pathway pairs, in which the lncRNA plays an immunomodulatory role in cancer by acting on the immune pathway.</p>
      </sec>
    </sec>
    <sec id="s2-4">
      <title>2.4 Pathogenicity Evaluation of Immune-Related lncRNAs</title>
      <p>After identifying cancer-related irlncRNAs, we further analyzed these irlncRNAs to explore their pathogenicity levels.</p>
      <sec id="s2-4-1">
        <title>2.4.1 Differential Expression Analysis of Immune-Related lncRNAs</title>
        <p>Since the differential expression level of lncRNA greatly influences on the pathogenicity of lncRNA, we performed differential expression analysis of the identified irlncRNAs in 33 cancers by using the edger package of R software. Here, the fold change and the adjusted <italic>p</italic> values were used to evaluate the expression differences of irlncRNAs, and the differentially expressed irlncRNAs were acquired by setting the adjusted <italic>p</italic>-value <inline-formula id="inf1"><mml:math id="m10" overflow="scroll"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 0.01 and the absolute value of logFC <inline-formula id="inf2"><mml:math id="m11" overflow="scroll"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 1.5. <italic>R</italic>
<sub><italic>DE</italic></sub>(<italic>l</italic>) is used to reflect the range of differential expression of irlncRNA <italic>l</italic> in set <italic>I</italic> and is defined as follows:<disp-formula id="e10"><mml:math id="m12" overflow="scroll"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mfenced open="[" close="]"><mml:mrow><mml:mi>N</mml:mi><mml:mi>C</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math><label>(10)</label></disp-formula>where function <italic>N</italic> is used for normalization, and <italic>NC</italic>(<italic>l</italic>) represents the number of cancers in which irlncRNA <italic>l</italic> from set <italic>I</italic> is differentially expressed. The range of <italic>NC</italic>(<italic>l</italic>) is [0, 24], and the upper limit depends on the number of cancers (with tumor and normal samples) for which we performed differential expression analysis. <italic>R</italic>
<sub><italic>FC</italic></sub>(<italic>l</italic>) is used to reflect the intensity of differential expression of irlncRNA <italic>l</italic> in set <italic>I</italic> and is defined as follows:<disp-formula id="e11"><mml:math id="m13" overflow="scroll"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mfenced open="[" close="]"><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mo movablelimits="false" form="prefix">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>C</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msubsup><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>C</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math><label>(11)</label></disp-formula>where function <italic>N</italic> is used for normalization, and <italic>FC</italic>(<italic>c</italic>, <italic>l</italic>) represents the fold change of the expression value of irlncRNA <italic>l</italic> in cancer <italic>c</italic>.</p>
      </sec>
      <sec id="s2-4-2">
        <title>2.4.2 Pathogenicity Prediction of Immune-Related lncRNAs</title>
        <p>Because the number of cancers related to lncRNA-pathway pairs and the differential expression level of lncRNA have a great influence on the pathogenicity level of lncRNA, we merged these two kinds of information to evaluate the pathogenicity level of irlncRNA <italic>l</italic> in set <italic>I</italic> as follows:<disp-formula id="e12"><mml:math id="m14" overflow="scroll"><mml:mi>P</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mo movablelimits="false" form="prefix">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>w</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>17</mml:mn></mml:mrow></mml:msubsup><mml:mi>N</mml:mi><mml:mfenced open="[" close="]"><mml:mrow><mml:mi>N</mml:mi><mml:mi>C</mml:mi><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>19</mml:mn></mml:mrow></mml:mfrac></mml:math><label>(12)</label></disp-formula>where function <italic>N</italic> is used for normalization, and <italic>NC</italic>(<italic>l</italic>, <italic>w</italic>) represents the number of cancers in which lncRNA <italic>l</italic> regulates immune pathway <italic>w</italic>.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>3 Results</title>
    <p>We proposed a computational method, ImReLnc, to identify irlncRNAs and predict their pathogenicity levels across cancer types (<xref rid="F1" ref-type="fig">Figure 1</xref>). The immunological and pathogenic properties of the identified irlncRNAs have been verified in this section. In particular, the experiment was performed on R 3.4.1 under Ubuntu 20.04.2, the CUDA version was 11.3, and the memory was 8 × 11019 M.</p>
    <sec id="s3-1">
      <title>3.1 Immune-Related lncRNAs and Pathways</title>
      <p>Through steps one to three in <xref rid="F1" ref-type="fig">Figure 1</xref>, we comprehensively analyzed the heuristic correlation between mRNA and lncRNA of 33 cancers and the enrichment of lncRNA in 17 immune pathways. As a result, we obtained a series of lncRNA-pathway pairs (<xref rid="F3" ref-type="fig">Figure 3</xref>) for each cancer. We found that the number of irlncRNA involved and the enriched immune pathways differed between cancers, and the degree of enrichment of cancers in some immune pathways tended to be similar. We further calculated the number of cancer-related irlncRNAs (<xref rid="F4" ref-type="fig">Figure 4A</xref>) and immune pathways (<xref rid="F4" ref-type="fig">Figure 4B</xref>). It was found that the number of cancer-related irlncRNAs ranged from 6.75 to 11.21 (after log2). Specifically, the number of UCEC-related irlncRNAs was the least at 6.75 (after log2), and the number of CHOL-related irlncRNAs was the highest at 11.21 (after log2). As for the number of cancer-related immune pathways, they ranged from 11 to 17. It should be noted that among 33 types of cancers, two types (6.1%) were enriched in 11 pathways, one type (3%) was enriched in 13 pathways, two types (6.1%) were enriched in 14 pathways, eight types (24.2%) were enriched in 15 pathways, thirteen types (39.4%) were enriched in 16 pathways, and the remaining seven types (21.2%) were enriched in 17 pathways. We found that the number of cancer types enriched in more than 16 pathways accounted for 60.6% of the total cancer types, and the number of cancer types enriched in more than 15 pathways accounted for 84.8% of the total cancer types. This indicates that most of the pathways are involved in the immune regulation process of cancer.</p>
      <fig position="float" id="F3">
        <label>FIGURE 3</label>
        <caption>
          <p>The distribution of lncRNA-pathway pairs in cancers. The lncRNAs in the lncRNA-pathway pairs refer to the immune-related lncRNAs (irlncRNAs), and the pathways in the lncRNA-pathway pairs refer to the immune pathways. Bubbles with different colors indicate the distribution of lncRNA-pathway pairs in different immune pathways, and the size of the bubbles is proportional to the number of irlncRNAs.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g003" position="float"/>
      </fig>
      <fig position="float" id="F4">
        <label>FIGURE 4</label>
        <caption>
          <p>The number of immune-related lncRNAs and immune pathways in cancer. <bold>(A)</bold> The log value of the number of immune-related lncRNAs in cancer. The size of the bubbles is proportional to the log value of the number of immune-related lncRNAs. <bold>(B)</bold> The number of immune pathways in cancer. The size of the bubble is proportional to the number of immune pathways.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g004" position="float"/>
      </fig>
      <p>Compared with cancers with a small number of lncRNA-pathway pairs, cancers with a large number of lncRNA-pathway pairs are more likely to be enriched in the immune pathway, and for the convenience of description, we refer to these cancers as immune-preferred cancers in the following text. We analyzed the enrichment of cancers in immune pathways to find immune-preferred cancers (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Cholangiocarcinoma (CHOL), Kidney Chromophobe (KICH), Testicular Germ Cell Tumors (TGCT), Thyroid carcinoma (THCA), and Thymoma (THYM) were found to have more obvious immune enrichment, thus they are the so-called immune-preferred cancers. Studies have shown that immunotherapy plays an important role in the treatment of these five types of cancer (<xref rid="B50" ref-type="bibr">Schott et al., 2001</xref>; <xref rid="B13" ref-type="bibr">Drake and Stein, 2018</xref>; <xref rid="B26" ref-type="bibr">Høgdall et al., 2018</xref>; <xref rid="B29" ref-type="bibr">Jakopovic et al., 2020</xref>; <xref rid="B32" ref-type="bibr">Kalavska et al., 2020</xref>). For these cancers, immunotherapy can achieve better prognostic effects, and our findings can provide a reference for their immunotherapy.</p>
      <fig position="float" id="F5">
        <label>FIGURE 5</label>
        <caption>
          <p>The enrichment of lncRNA-pathway pairs in cancers and immune pathways. The p1-17 represents Antigen Processing and Presentation, Antimicrobials, BCRSignalingPathway, Chemokine Receptors, Chemokines, Cytokine Receptors, Cytokines, Interferons, Interferons Receptor, Interleukins, Interleukins Receptor, NaturalKiller Cell Cytotoxicity, TCRsignalingPathway, TGFb Family Member, TGFb Family Member Receptor, TNF Family Members, and TNF Family Members Receptors respectively. <bold>(A)</bold> The Enrichment of lncRNA-pathway pairs in cancers. <bold>(B)</bold> The Enrichment of lncRNA-pathway pairs in immune pathways.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g005" position="float"/>
      </fig>
      <p>Cancers also have a preference for their enriched immune pathways. They will be mainly enriched in some immune pathways, which we call highly enriched immune pathways, while their enrichment in other pathways will be very limited. We analyzed the distribution of lncRNA-pathway pairs on the immune pathways to discover highly enriched immune pathways in cancers (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Cancers were mainly enriched in 5 immune pathways (Antigen Processing and Presentation, Antimicrobials, Cytokine Receptors, Cytokines, and NaturalKiller Cell Cytotoxicity), and the average enrichment ratio of lncRNA-pathway pairs related to these pathways was 0.790 832 3. Specifically, 18 of 33 (more than half) cancers were enriched in these five immune pathways by more than 0.790 832 3 (<xref rid="F6" ref-type="fig">Figure 6</xref>). Obviously, these five pathways are highly enriched immune pathways for those 33 cancers, and these pathways are active in the immune regulation process of the cancers. Antigen processing and presentation is involved in the decomposition and presentation of antigen proteins in immune regulation (<xref rid="B58" ref-type="bibr">Vyas et al., 2008</xref>). Antimicrobials are related to the life activities of bacteria (<xref rid="B57" ref-type="bibr">Van Harten et al., 2018</xref>). Cytokine Receptors and Cytokines play a signal transduction role in immune regulation (<xref rid="B46" ref-type="bibr">O’Shea et al., 2019</xref>). As for NaturalKiller Cell Cytotoxicity, it is related to the immune regulation of NaturalKiller Cell (<xref rid="B56" ref-type="bibr">Topham and Hewitt, 2009</xref>). The functions mentioned above are related to the life activities of cancer cells, thus the high enrichment of these five immune pathways is closely related to the occurrence of cancer.</p>
      <fig position="float" id="F6">
        <label>FIGURE 6</label>
        <caption>
          <p>The enrichment of cancers in the highly enriched immune pathways. The size of the bubbles is proportional to the ratio of cancer in the highly enriched immune pathway.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g006" position="float"/>
      </fig>
    </sec>
    <sec id="s3-2">
      <title>3.2 The Distribution of Immune-Related lncRNAs</title>
      <p>Cancers are enriched in immune pathways with a series of lncRNA-pathway pairs, and each pathway is related to a variety of lncRNAs which are the irlncRNAs to be recognized. These irlncRNAs are involved in the immune regulation process of cancer. We analyzed the characteristics of cancers and immune pathways related to them (See <xref rid="s10" ref-type="sec">Supplementary Table S1, 2</xref>). It was found that the total number of irlncRNAs was 7,038, the number of cancers related to irlncRNA ranged from 1 to 32, and the number of immune pathways associated with irlncRNA ranged from 1 to 15. For the number of cancers and pathways in these ranges, we further explored the distribution of irlncRNAs on them (See <xref rid="s10" ref-type="sec">Supplementary Figure S2</xref>, Data Sheet 1). Firstly, for the distribution of different numbers of cancers, we found that irlncRNAs related to only one type of cancer accounted for 0.417 448 1 of the total irlncRNAs, irlncRNAs related to two types of cancer accounted for 0.209 718 7 of the total irlncRNAs, irlncRNAs related to three types of cancer accounted for 0.114 237 of the total irlncRNAs, and the remaining 4–32 types of cancer-related irlncRNAs accounted for 0.258 596 2 of the total irlncRNAs. Then, for the distribution of different numbers of immune pathways, we found that irlncRNAs associated with one to four immune pathways accounted for 0.638 107 4 of the total irlncRNAs, and the remaining 0.361 892 6 of irlncRNAs were related to 5–15 pathways. Overall, more than half of irlncRNAs played a regulatory role in several types of cancer, and these regulatory roles involved multiple immune pathways.</p>
      <p>The immunomodulatory effect in immune-preferred cancers is quite active, and we further analyzed irlncRNAs related to these cancers (See <xref rid="s10" ref-type="sec">Supplementary Table S3</xref>). There were 34 irlncRNAs related to all five immune-preferred cancers, and another 5,097 irlncRNAs were related to one to four of the five immune-preferred cancers. The highly enriched immune pathway plays an important role in the immune regulation of cancers. Thus we obtained irlncRNAs related to the highly enriched pathways (See <xref rid="s10" ref-type="sec">Supplementary Table S4</xref>). There were 1,264 irlncRNAs related to all five highly enriched immune pathways, and another 5,473 irlncRNAs were related to one to four of the five highly enriched immune pathways. Obviously, most irlncRNAs (0.627 558) were involved in one of the five immune-preferred cancers, and they were almost evenly distributed in the five pathways. This was significantly different from the distribution of irlncRNAs in total cancers and total immune pathways due to the immune preference of the cancers and the high enrichment of the immune pathways.</p>
    </sec>
    <sec id="s3-3">
      <title>3.3 The Expression of Immune-Related lncRNAs</title>
      <p>Since the immune regulation process is performed by immune cells, the expression of irlncRNA in immune cells should be higher than that in other cells. We compared the expression levels of irlncRNA and non-irlncRNA in immune and non-immune cells on single-cell sequencing data from the PanglaoDB database. 1) We normalized the single-cell sequencing data of hepatic carcinoma. 2) The lncRNA count data was extracted. 3) The irlncRNA count data and non-irlncRNA count data were extracted. 4) We compared the expression of irlncRNA and non-irlncRNA in immune and non-immune cells, respectively (<xref rid="F7" ref-type="fig">Figures 7A–C</xref>). It was found that the average expression of irlncRNA in immune cells was higher than that of non-irlncRNA, while in non-immune cells, their difference was slight (<xref rid="F7" ref-type="fig">Figure 7A</xref>). The distributions of irlncRNA and non-irlncRNA in immune cells and non-immune cells further confirmed this conclusion (<xref rid="F7" ref-type="fig">Figures 7B,C</xref>). To further explore the expression characteristics of irlncRNA, we analyzed the correlation between lncRNA expression and the level of immune infiltration in cancers. We first estimated the immune infiltration level of cancer samples through the TIMER online tool (<xref rid="B44" ref-type="bibr">Newman et al., 2015</xref>; <xref rid="B5" ref-type="bibr">Becht et al., 2016</xref>; <xref rid="B34" ref-type="bibr">Li et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>; <xref rid="B16" ref-type="bibr">Finotello et al., 2019</xref>). Then, we calculated the correlation between lncRNA expression and the level of immune infiltration to find out infiltration-related lncRNAs (infrlncRNAs). Finally, we compared the distribution of our method (ImReLnc) and ImmLnc on irlncRNA and infrlncRNA. Specifically, we calculated the irlnRNA rate (IR) in all lncRNAs, the irlnRNA rate in infrlncRNA (IRINF), the infrlncRNA rate (INFR) in all lncRNAs, the infrlncRNA rate in irlncRNA (INFRI) for ImReLnc and ImmLnc (See <xref rid="s10" ref-type="sec">Supplementary Table S3, S4</xref>, Data Sheet 1). It was found that the IRINF/IR and IRINF/IR of ImReLnc were significantly higher than ImmLnc in all 33 cancers (See <xref rid="s10" ref-type="sec">Supplementary Figure S3</xref>, Data Sheet 1). Therefore, the irlncRNAs recognized by ImReLnc have more significant immune properties than those recognized by ImmLnc.</p>
      <fig position="float" id="F7">
        <label>FIGURE 7</label>
        <caption>
          <p>The expression of immune-related lncRNA (irlncRNA) and non-immune-related lncRNA (non-irlncRNA) in immune and non-immune cells. <bold>(A)</bold> The average expression of irlncRNA and non-irlncRNA in immune cells and non-immune cells. <bold>(B)</bold> The distribution of irlncRNA and non-irlncRNA in immune cells (<italic>p</italic>-value ≤0.01). <bold>(C)</bold> The distribution of irlncRNA and non-irlncRNA in non-immune cells (<italic>p</italic>-value ≤0.01).</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g007" position="float"/>
      </fig>
      <p>In order to show that the heuristic correlation coefficient is better than the direct or partial correlation coefficient, we performed the following analysis on the colon cancer data set. First, we calculated three correlation coefficients: direct correlation coefficient, partial correlation coefficient, and heuristic correlation coefficient. Then, we performed immune-related enrichment analysis based on the above correlation coefficients. Afterward, we screened the enrichment results and obtained three sets of irlncRNAs. Finally, we performed Cox regression analysis on the three groups of irlncRNAs. Specifically, six highly pathogenic irlncRNAs RP5-884M6.1, RP11-742B18.1, HOTAIR, AC004988.1, CTD-2357A8.3, and GS1-600G8.5, were found to be associated with cancer prognosis (<xref rid="T1" ref-type="table">Table 1</xref>). Among them, RP5-884M6.1, RP11-742B18.1, and HOTAIR were found to be related to the occurrence of colon cancer by previous studies (<xref rid="B69" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="B47" ref-type="bibr">Paredes et al., 2020</xref>; <xref rid="B24" ref-type="bibr">Gong et al., 2021</xref>). The prognostic analysis related to the three correlation calculations is shown in <xref rid="F8" ref-type="fig">Figure 8</xref>. We found that the prognostic effects of lncRNA calculated by direct correlation and partial correlation were not much different. The prognostic effect of lncRNA calculated by heuristic correlation was better than the former two. This indicates that heuristic correlation calculation has advantages in identifying immune-related prognostic characteristics in cancer.</p>
      <table-wrap position="float" id="T1">
        <label>TABLE 1</label>
        <caption>
          <p>Univariate and Multivariate Cox analysis of immune-related lncRNAs.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th rowspan="2" align="left" colspan="1">LncRNA</th>
              <th colspan="2" align="center" rowspan="1">Univariate</th>
              <th colspan="3" align="center" rowspan="1">Multivariate</th>
              <th rowspan="2" align="center" colspan="1">Source</th>
            </tr>
            <tr>
              <th align="center" rowspan="1" colspan="1">HR (95% CI for HR)</th>
              <th align="center" rowspan="1" colspan="1">p.value</th>
              <th align="center" rowspan="1" colspan="1">Coef</th>
              <th align="center" rowspan="1" colspan="1">z</th>
              <th align="center" rowspan="1" colspan="1">p</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">HOTAIR</td>
              <td align="char" char="(" rowspan="1" colspan="1">0.97 (0.95–0.99)</td>
              <td align="center" rowspan="1" colspan="1">0.026</td>
              <td align="center" rowspan="1" colspan="1">5.79E-03</td>
              <td align="char" char="." rowspan="1" colspan="1">1.914</td>
              <td align="center" rowspan="1" colspan="1">0.001 58</td>
              <td align="center" rowspan="1" colspan="1">PMID: 34 630 664</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">AC004988.1</td>
              <td align="char" char="(" rowspan="1" colspan="1">1 (1–1)</td>
              <td align="center" rowspan="1" colspan="1">0.000 19</td>
              <td align="center" rowspan="1" colspan="1">-4.88E-04</td>
              <td align="char" char="." rowspan="1" colspan="1">-1.638</td>
              <td align="center" rowspan="1" colspan="1">0.001 66</td>
              <td align="center" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RP5-884M6.1</td>
              <td align="char" char="(" rowspan="1" colspan="1">1 (1–1)</td>
              <td align="center" rowspan="1" colspan="1">0.001 9</td>
              <td align="center" rowspan="1" colspan="1">1.83E-03</td>
              <td align="char" char="." rowspan="1" colspan="1">2.92</td>
              <td align="center" rowspan="1" colspan="1">0.003 56</td>
              <td align="center" rowspan="1" colspan="1">PMID: 32 983 990</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CTD-2357A8.3</td>
              <td align="char" char="(" rowspan="1" colspan="1">0.97 (0.95–0.99)</td>
              <td align="center" rowspan="1" colspan="1">0.007 2</td>
              <td align="center" rowspan="1" colspan="1">-0.001 200 4</td>
              <td align="char" char="." rowspan="1" colspan="1">-1.387</td>
              <td align="center" rowspan="1" colspan="1">0.015 35</td>
              <td align="center" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">GS1-600G8.5</td>
              <td align="char" char="(" rowspan="1" colspan="1">0.99 (0.98–1)</td>
              <td align="center" rowspan="1" colspan="1">0.012</td>
              <td align="center" rowspan="1" colspan="1">1.19E-02</td>
              <td align="char" char="." rowspan="1" colspan="1">1.154</td>
              <td align="center" rowspan="1" colspan="1">0.029 29</td>
              <td align="center" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RP11-742B18.1</td>
              <td align="char" char="(" rowspan="1" colspan="1">1 (1–1)</td>
              <td align="center" rowspan="1" colspan="1">0.000 98</td>
              <td align="center" rowspan="1" colspan="1">-3.10E-02</td>
              <td align="char" char="." rowspan="1" colspan="1">-2.045</td>
              <td align="center" rowspan="1" colspan="1">0.040 83</td>
              <td align="center" rowspan="1" colspan="1">PMID: 31 516 583</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig position="float" id="F8">
        <label>FIGURE 8</label>
        <caption>
          <p>Kaplan-Meier curves of immune-related lncRNAs from different correlation calculations. <bold>(A)</bold> Direct correlation calculation in the training set. <bold>(B)</bold> Direct correlation calculation in the testing set. <bold>(C)</bold> Direct correlation calculation in the total set. <bold>(D)</bold> Partial correlation calculation in the training set. <bold>(E)</bold> Partial correlation calculation in the testing set. <bold>(F)</bold> Partial correlation calculation in the total set. <bold>(G)</bold> Heuristic correlation calculation in the training set. <bold>(H)</bold> Heuristic correlation calculation in the testing set. <bold>(I)</bold> Heuristic correlation calculation in the total set.</p>
        </caption>
        <graphic xlink:href="fgene-12-792541-g008" position="float"/>
      </fig>
    </sec>
    <sec id="s3-4">
      <title>3.4 The Pathogenicity Level of Immune-Related lncRNAs</title>
      <p>Having proved that ImReLnc can effectively identify irlncRNA, we next explored the application of ImReLnc in assessing the pathogenicity level of irlncRNA. We first compared the relationship between drlncRNAs from disease databases (LncRNADisease2.0 and Lnc2Cancer2.0) and irlncRNAs recognized by ImmLnc and ImmLnc. Specifically, the top 500 irlncRNAs (determined by the number of cancers involved in irlncRNA) were used for analysis, and we found that the irlncRNA recognized by ImReLnc accounted for a higher proportion in the disease database (<xref rid="T2" ref-type="table">Table 2</xref>). Besides, we analyzed the distribution of pathogenicity levels of irlncRNAs in ImReLnc. Two methods were used to divide the data set where the sorted irlncRNAs (descending order) were located. The first method was to evenly divide irlncRNAs into 6 data sets according to the number of irlncRNAs (<xref rid="T3" ref-type="table">Table 3</xref>), and the second method was to divide irlncRNAs into 5 data sets evenly according to the level of pathogenicity of irlncRNAs (<xref rid="T4" ref-type="table">Table 4</xref>). In <xref rid="T3" ref-type="table">Table 3</xref>, the average pathogenicity level of irlncRNAs in LncRNADisease2.0 and Lnc2Cancer2.0 is higher than or approximately equal to that of all identified irlncRNAs, especially in Dataset 1. This indicates that the calculated pathogenicity level of irlncRNA is credible, and irlncRNA is particularly pathogenic within the range of high pathogenicity levels. Similarly, in the range of high pathogenicity levels in <xref rid="T4" ref-type="table">Table 4</xref>, the mean pathogenicity level of irlncRNAs in LncRNADisease2.0 and Lnc2Cancer2.0 is higher than the mean pathogenicity level of all identified irlncRNAs. This further shows that the calculated pathogenicity level of irlncRNA is credible, and its pathogenicity within the interval of high pathogenicity level is quite apparent.</p>
      <table-wrap position="float" id="T2">
        <label>TABLE 2</label>
        <caption>
          <p>The comparison of the relationship between irlncRNA and drlncRNA in ImmLnc and ImReLnc. The data set in the table is divided equally according to the number of irlncRNAs. IrlncRNAs refer to immune-related lncRNAs, drlncRNA refers to disease-related lncRNAs.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th rowspan="2" align="left" colspan="1">Dataset</th>
              <th colspan="3" align="center" rowspan="1">Distribution of ImReLnc</th>
              <th colspan="3" align="center" rowspan="1">Distribution of ImmLnc</th>
            </tr>
            <tr>
              <th align="center" rowspan="1" colspan="1">Count</th>
              <th align="center" rowspan="1" colspan="1">LncRNADisease2.0</th>
              <th align="center" rowspan="1" colspan="1">Lnc2Cancer2.0</th>
              <th align="center" rowspan="1" colspan="1">Count</th>
              <th align="center" rowspan="1" colspan="1">LncRNADisease2.0</th>
              <th align="center" rowspan="1" colspan="1">Lnc2Cancer2.0</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">Total</td>
              <td align="center" rowspan="1" colspan="1">500</td>
              <td align="center" rowspan="1" colspan="1">110</td>
              <td align="center" rowspan="1" colspan="1">111</td>
              <td align="center" rowspan="1" colspan="1">500</td>
              <td align="center" rowspan="1" colspan="1">106</td>
              <td align="center" rowspan="1" colspan="1">109</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Dataset1</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">29</td>
              <td align="center" rowspan="1" colspan="1">25</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">27</td>
              <td align="center" rowspan="1" colspan="1">22</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Dataset2</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">27</td>
              <td align="center" rowspan="1" colspan="1">29</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">28</td>
              <td align="center" rowspan="1" colspan="1">25</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Dataset3</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">30</td>
              <td align="center" rowspan="1" colspan="1">31</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">25</td>
              <td align="center" rowspan="1" colspan="1">29</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Dataset4</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">14</td>
              <td align="center" rowspan="1" colspan="1">11</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">15</td>
              <td align="center" rowspan="1" colspan="1">20</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Dataset5</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">10</td>
              <td align="center" rowspan="1" colspan="1">15</td>
              <td align="center" rowspan="1" colspan="1">100</td>
              <td align="center" rowspan="1" colspan="1">11</td>
              <td align="center" rowspan="1" colspan="1">13</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap position="float" id="T3">
        <label>TABLE 3</label>
        <caption>
          <p>The pathogenicity distribution of immune-related lncRNA (irlncRNA). The data set is divided equally according to the number of irlncRNAs.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Pathogenicity level of IrlncRNA</th>
              <th align="center" rowspan="1" colspan="1">Total</th>
              <th align="center" rowspan="1" colspan="1">Dataset1</th>
              <th align="center" rowspan="1" colspan="1">Dataset2</th>
              <th align="center" rowspan="1" colspan="1">Dataset3</th>
              <th align="center" rowspan="1" colspan="1">Dataset4</th>
              <th align="center" rowspan="1" colspan="1">Dataset5</th>
              <th align="center" rowspan="1" colspan="1">Dataset6</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">All identified irlncRNAs</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count</td>
              <td align="center" rowspan="1" colspan="1">7,038</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
              <td align="center" rowspan="1" colspan="1">1,173</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min</td>
              <td align="center" rowspan="1" colspan="1">0.028 1</td>
              <td align="center" rowspan="1" colspan="1">0.345 5</td>
              <td align="center" rowspan="1" colspan="1">0.298 8</td>
              <td align="center" rowspan="1" colspan="1">0.263 2</td>
              <td align="center" rowspan="1" colspan="1">0.231 8</td>
              <td align="center" rowspan="1" colspan="1">0.197 7</td>
              <td align="center" rowspan="1" colspan="1">0.028 1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.345 4</td>
              <td align="center" rowspan="1" colspan="1">0.298 8</td>
              <td align="center" rowspan="1" colspan="1">0.263 1</td>
              <td align="center" rowspan="1" colspan="1">0.231 8</td>
              <td align="center" rowspan="1" colspan="1">0.197 7</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.271 3</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.399 9</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.320 2</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.280 6</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.247 6</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.215 4</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.164 2</bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">In LncRNADisease2.0</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count1</td>
              <td align="center" rowspan="1" colspan="1">613</td>
              <td align="center" rowspan="1" colspan="1">202</td>
              <td align="center" rowspan="1" colspan="1">111</td>
              <td align="center" rowspan="1" colspan="1">102</td>
              <td align="center" rowspan="1" colspan="1">63</td>
              <td align="center" rowspan="1" colspan="1">61</td>
              <td align="center" rowspan="1" colspan="1">74</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count1/Count</td>
              <td align="center" rowspan="1" colspan="1">0.087 1</td>
              <td align="center" rowspan="1" colspan="1">0.172 2</td>
              <td align="center" rowspan="1" colspan="1">0.094 6</td>
              <td align="center" rowspan="1" colspan="1">0.087</td>
              <td align="center" rowspan="1" colspan="1">0.053 7</td>
              <td align="center" rowspan="1" colspan="1">0.052</td>
              <td align="center" rowspan="1" colspan="1">0.063 1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min1</td>
              <td align="center" rowspan="1" colspan="1">0.108 7</td>
              <td align="center" rowspan="1" colspan="1">0.346</td>
              <td align="center" rowspan="1" colspan="1">0.299</td>
              <td align="center" rowspan="1" colspan="1">0.263 3</td>
              <td align="center" rowspan="1" colspan="1">0.232 3</td>
              <td align="center" rowspan="1" colspan="1">0.197 8</td>
              <td align="center" rowspan="1" colspan="1">0.108 7</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max1</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.345 3</td>
              <td align="center" rowspan="1" colspan="1">0.298 6</td>
              <td align="center" rowspan="1" colspan="1">0.262 8</td>
              <td align="center" rowspan="1" colspan="1">0.231</td>
              <td align="center" rowspan="1" colspan="1">0.197 6</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean1</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.308 2</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.415 5</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.322 6</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.279 7</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.248 3</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.213 9</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.161 6</bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">In Lnc2Cancer2.0</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count2</td>
              <td align="center" rowspan="1" colspan="1">666</td>
              <td align="center" rowspan="1" colspan="1">181</td>
              <td align="center" rowspan="1" colspan="1">115</td>
              <td align="center" rowspan="1" colspan="1">114</td>
              <td align="center" rowspan="1" colspan="1">93</td>
              <td align="center" rowspan="1" colspan="1">77</td>
              <td align="center" rowspan="1" colspan="1">86</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count2/Count</td>
              <td align="center" rowspan="1" colspan="1">0.094 6</td>
              <td align="center" rowspan="1" colspan="1">0.154 3</td>
              <td align="center" rowspan="1" colspan="1">0.098</td>
              <td align="center" rowspan="1" colspan="1">0.097 2</td>
              <td align="center" rowspan="1" colspan="1">0.079 3</td>
              <td align="center" rowspan="1" colspan="1">0.065 6</td>
              <td align="center" rowspan="1" colspan="1">0.073 3</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min2</td>
              <td align="center" rowspan="1" colspan="1">0.091 5</td>
              <td align="center" rowspan="1" colspan="1">0.345 5</td>
              <td align="center" rowspan="1" colspan="1">0.299</td>
              <td align="center" rowspan="1" colspan="1">0.263 3</td>
              <td align="center" rowspan="1" colspan="1">0.231 8</td>
              <td align="center" rowspan="1" colspan="1">0.197 9</td>
              <td align="center" rowspan="1" colspan="1">0.091 5</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max2</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.345 3</td>
              <td align="center" rowspan="1" colspan="1">0.298 6</td>
              <td align="center" rowspan="1" colspan="1">0.263 1</td>
              <td align="center" rowspan="1" colspan="1">0.231 6</td>
              <td align="center" rowspan="1" colspan="1">0.196 8</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean2</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.295 9</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.411 1</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.321 3</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.280 8</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.249</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.214 5</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.163 3</bold>
              </td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap position="float" id="T4">
        <label>TABLE 4</label>
        <caption>
          <p>The pathogenicity distribution of immune-related lncRNA (irlncRNA). The data set is divided equally according to the pathogenicity level of irlncRNAs.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Pathogenicity level of IrlncRNA</th>
              <th align="center" rowspan="1" colspan="1">Total</th>
              <th align="center" rowspan="1" colspan="1">Dataset1</th>
              <th align="center" rowspan="1" colspan="1">Dataset2</th>
              <th align="center" rowspan="1" colspan="1">Dataset3</th>
              <th align="center" rowspan="1" colspan="1">Dataset4</th>
              <th align="center" rowspan="1" colspan="1">Dataset5</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">All identified irlncRNAs</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count</td>
              <td align="center" rowspan="1" colspan="1">7,038</td>
              <td align="center" rowspan="1" colspan="1">156</td>
              <td align="center" rowspan="1" colspan="1">1,000</td>
              <td align="center" rowspan="1" colspan="1">3,212</td>
              <td align="center" rowspan="1" colspan="1">2582</td>
              <td align="center" rowspan="1" colspan="1">88</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min</td>
              <td align="center" rowspan="1" colspan="1">0.028 1</td>
              <td align="center" rowspan="1" colspan="1">0.452 6</td>
              <td align="center" rowspan="1" colspan="1">0.346 5</td>
              <td align="center" rowspan="1" colspan="1">0.240 3</td>
              <td align="center" rowspan="1" colspan="1">0.134 3</td>
              <td align="center" rowspan="1" colspan="1">0.028 1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.452 5</td>
              <td align="center" rowspan="1" colspan="1">0.346 4</td>
              <td align="center" rowspan="1" colspan="1">0.240 3</td>
              <td align="center" rowspan="1" colspan="1">0.133 8</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.271 3</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.483 8</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.387 8</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.287 8</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.198 2</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.114 3</bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">In LncRNADisease2.0</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count1</td>
              <td align="center" rowspan="1" colspan="1">613</td>
              <td align="center" rowspan="1" colspan="1">47</td>
              <td align="center" rowspan="1" colspan="1">153</td>
              <td align="center" rowspan="1" colspan="1">263</td>
              <td align="center" rowspan="1" colspan="1">143</td>
              <td align="center" rowspan="1" colspan="1">7</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count1/Count</td>
              <td align="center" rowspan="1" colspan="1">0.087 1</td>
              <td align="center" rowspan="1" colspan="1">0.301 3</td>
              <td align="center" rowspan="1" colspan="1">0.153</td>
              <td align="center" rowspan="1" colspan="1">0.081 9</td>
              <td align="center" rowspan="1" colspan="1">0.055 4</td>
              <td align="center" rowspan="1" colspan="1">0.079 5</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min1</td>
              <td align="center" rowspan="1" colspan="1">0.108 7</td>
              <td align="center" rowspan="1" colspan="1">0.452 6</td>
              <td align="center" rowspan="1" colspan="1">0.346 5</td>
              <td align="center" rowspan="1" colspan="1">0.240 5</td>
              <td align="center" rowspan="1" colspan="1">0.135 5</td>
              <td align="center" rowspan="1" colspan="1">0.108 7</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max1</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.451 7</td>
              <td align="center" rowspan="1" colspan="1">0.346 4</td>
              <td align="center" rowspan="1" colspan="1">0.240 2</td>
              <td align="center" rowspan="1" colspan="1">0.132 8</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean1</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.308 2</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.490 6</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.393 3</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.293 2</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.193 5</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.126 1</bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">In Lnc2Cancer2.0</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count2</td>
              <td align="center" rowspan="1" colspan="1">666</td>
              <td align="center" rowspan="1" colspan="1">36</td>
              <td align="center" rowspan="1" colspan="1">143</td>
              <td align="center" rowspan="1" colspan="1">300</td>
              <td align="center" rowspan="1" colspan="1">177</td>
              <td align="center" rowspan="1" colspan="1">10</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Count2/Count</td>
              <td align="center" rowspan="1" colspan="1">0.094 6</td>
              <td align="center" rowspan="1" colspan="1">0.230 8</td>
              <td align="center" rowspan="1" colspan="1">0.143</td>
              <td align="center" rowspan="1" colspan="1">0.093 4</td>
              <td align="center" rowspan="1" colspan="1">0.068 6</td>
              <td align="center" rowspan="1" colspan="1">0.113 6</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Min2</td>
              <td align="center" rowspan="1" colspan="1">0.091 5</td>
              <td align="center" rowspan="1" colspan="1">0.452 6</td>
              <td align="center" rowspan="1" colspan="1">0.346 5</td>
              <td align="center" rowspan="1" colspan="1">0.240 9</td>
              <td align="center" rowspan="1" colspan="1">0.141 2</td>
              <td align="center" rowspan="1" colspan="1">0.091 5</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Max2</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.558 7</td>
              <td align="center" rowspan="1" colspan="1">0.45</td>
              <td align="center" rowspan="1" colspan="1">0.346</td>
              <td align="center" rowspan="1" colspan="1">0.240 2</td>
              <td align="center" rowspan="1" colspan="1">0.133 7</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"> Mean2</td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.295 9</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.488 4</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.392 6</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.290 5</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.197 8</bold>
              </td>
              <td align="center" rowspan="1" colspan="1">
                <bold>0.121 7</bold>
              </td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>4 Discussion</title>
    <p>Long non-coding RNA plays an essential role in cancer via gene expression and immune regulation (<xref rid="B27" ref-type="bibr">Hu et al., 2013</xref>; <xref rid="B10" ref-type="bibr">Chen et al., 2017</xref>), and the identification of irlncRNA is of great significance to the diagnosis and treatment of cancer. This study implemented an R program, ImReLnc, to identify irlncRNAs and analyze their pathogenicity levels across cancer types. Firstly, ImReLnc calculated heuristic correlation based on direct correlation and partial correlation to provided a ranking score for lncRNA-related mRNA class. Then, ImReLnc performed immune-related enrichment analysis based on the ranking score mentioned above to obtain irlncRNAs. Besides, ImReLnc conducted differential expression analysis of these irlncRNAs. Finally, the pathogenicity levels of the irlncRNAs were estimated by their immune and differential expression characteristics across cancer types.</p>
    <p>We compared the expression levels of irlncRNAs in immune cells and non-immune cells, which showed that the expression of irlcRNAs in immune cells was higher than that in non-immune cells (<xref rid="F7" ref-type="fig">Figure 7</xref>). Besides, we analyzed the correlation between lncRNA expression and the level of immune infiltration. We found that the IR was significantly lower than the IRINF, and the INFR was also significantly lower than the INFRI, which indicated that the immunomodulatory effect of the identified irlncRNAs was significant (See <xref rid="s10" ref-type="sec">Supplementary Table S3</xref>, Data Sheet 1). Furthermore, for the irlncRNAs in each cancer identified by ImReLnc, we compared them with those identified by ImmLnc (See <xref rid="s10" ref-type="sec">Supplementary Table S5</xref>, Data Sheet 1). We found a significant overlap between the irlncRNAs recognized by the two methods, which further demonstrated the reliability of ImReLnc in recognizing irlncRNAs. Finally, we explored the application of ImReLnc in evaluating the pathogenicity level of irlncRNAs. For the pathogenicity levels of irlncRNAs estimated by ImReLnc, we compared them with the drlncRNAs in the disease database (<xref rid="T3" ref-type="table">Table 3</xref> and <xref rid="T3" ref-type="table">Table 3</xref>), and the results showed that drlncRNAs had a significantly higher proportion in the highly pathogenic irlncRNA interval. We also compared the relationship between drlncRNA (from the LncRNADisease and Lnc2Cancer disease databases) and irlncRNA (identified by ImmLnc and ImReLnc), and we found that the irlncRNA recognized by ImReLnc accounted for a higher proportion in the disease database (<xref rid="T2" ref-type="table">Table 2</xref>). This indicates that our calculation of the pathogenicity levels of irlnRNAs is credible.</p>
    <p>LncRNA FEZF1-AS1 was found to have the highest pathogenic level in cancer and was related to the occurrence of GBM, LUAD, HNSC, LGG, LUSC, PRAD, SKCM, BLCA, LIHC, READ, TGCT, THYM, ACC, MESO, UCS, and CHOL. We infer that lncRNA FEZF1-AS1 plays an important regulatory role in these 16 cancers. For GBM, LUAD, PRAD, LIHC, READ, and UCS, studies have shown that lncRNA FEZF1-AS1 plays a crucial regulatory role in them (<xref rid="B38" ref-type="bibr">Luo et al., 2020</xref>; <xref rid="B37" ref-type="bibr">Liu et al., 2018</xref>; <xref rid="B70" ref-type="bibr">Zhu et al., 2019</xref>; <xref rid="B60" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="B8" ref-type="bibr">Bian et al., 2018</xref>; <xref rid="B63" ref-type="bibr">Zhang and Li, 2018</xref>). As for the other ten types of cancer, their cancer tissues are similar to or adjacent to the cancer tissues of the above six types of cancer (See <xref rid="s10" ref-type="sec">Supplementary Table S6</xref>, Data Sheet 1). Studies have shown that cancers with similar original tissues may share lncRNA regulatory mechanisms (<xref rid="B64" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="B36" ref-type="bibr">Li et al., 2020</xref>). The original tissue of LGG is similar to GBM, the original tissue of LUSC and MESO is similar to LUAD, and the original tissue of CHOL is similar to LIHC. Therefore, like in their similar tissues, lncRNA FEZF1-AS1 may also play an immunoregulatory role in LGG, LUSC, MESO, and CHOL. The original tissue of THYM and HNSC is adjacent to GBM, the original tissue of ACC is adjacent to GBM, the original tissue of BLCA and TGCT is adjacent to PRAD, and the original tissue of SKCM is adjacent to UCS. These cancers may be caused by the metastasis of their adjacent tissues. Thus they have a similar irlncRNA regulatory mechanism as their adjacent tissues. Among them, ACC and SKCM are relatively far from their neighboring tissues, which may be caused by long-distance metastasis of advanced cancer. Overall, lncRNA FEZF1-AS1 is highly pathogenic and plays a crucial immunomodulatory role in cancer, which can provide a necessary reference for cancer treatment.</p>
    <p>In summary, ImReLnc accurately identified irlncRNAs in cancers based on heuristic correlation optimization. More importantly, ImReLnc effectively assessed the pathogenicity level of irlncRNAs based on their immune and differential expression characteristics. However, due to the limitation of data acquisition, ImReLnc can only identify irlncRNAs in 33 cancers. In addition, we identified genes related to lncRNA expression and further investigated the enriched immune pathways, but it is still challenging determine how specific lncRNA affects gene expression. In the future, we hope to perform irlncRNA recognition for other types of cancer and explore the targets of these irlncRNAs.</p>
  </sec>
</body>
<back>
  <ack>
    <p>We would like to thank all members of the laboratory for their valuable discussions and comments.</p>
  </ack>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>Publicly available datasets were analyzed in this study. This data can be found here: (1) TCGA: <ext-link xlink:href="https://portal.gdc.cancer.gov/" ext-link-type="uri">https://portal.gdc.cancer.gov/</ext-link>, (2) GENCODE: <ext-link xlink:href="https://www.gencodegenes.org/" ext-link-type="uri">https://www.gencodegenes.org/</ext-link>, (3) PanglaoDB: <ext-link xlink:href="https://panglaodb.se/index.html" ext-link-type="uri">https://panglaodb.se/index.html</ext-link>, (4) TIMER: <ext-link xlink:href="http://cistrome.dfci.harvard.edu/TIMER/" ext-link-type="uri">http://cistrome.dfci.harvard.edu/TIMER/</ext-link>, (5) LncRNADisease2.0: <ext-link xlink:href="http://www.rnanut.net/lncrnadisease/" ext-link-type="uri">http://www.rnanut.net/lncrnadisease/</ext-link>, (6) Lnc2Cancer2.0: <ext-link xlink:href="http://www.bio-bigdata.net/lnc2cancer2.0/index.html" ext-link-type="uri">http://www.bio-bigdata.net/lnc2cancer2.0/index.html</ext-link>, (7) Immport: <ext-link xlink:href="https://www.immport.org/home" ext-link-type="uri">https://www.immport.org/home</ext-link>.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>MG designed and implemented the method. MG, SL, YQ and XG wrote this manuscript. All authors read and approved the final manuscript.</p>
  </sec>
  <sec id="s7">
    <title>Funding</title>
    <p>Thanks for the support of the National Natural Science Foundation of China (grant numbers 61772426, U1811262).</p>
  </sec>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s9">
    <title>Publisher’s Note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <sec id="s10">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2021.792541/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fgene.2021.792541/full#supplementary-material</ext-link>
</p>
    <supplementary-material id="SM1" position="float" content-type="local-data">
      <media xlink:href="Table2.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SM2" position="float" content-type="local-data">
      <media xlink:href="Table3.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SM3" position="float" content-type="local-data">
      <media xlink:href="DataSheet1.PDF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SM4" position="float" content-type="local-data">
      <media xlink:href="Table4.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SM5" position="float" content-type="local-data">
      <media xlink:href="Table1.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>N. M.</given-names></name><name><surname>Simon</surname><given-names>M. C.</given-names></name></person-group> (<year>2020</year>). <article-title>The Tumor Microenvironment</article-title>. <source>Curr. Biol.</source>
<volume>30</volume>, <fpage>R921</fpage>–<lpage>R925</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2020.06.081</pub-id>
<pub-id pub-id-type="pmid">32810447</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Butte</surname><given-names>A. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Xcell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape</article-title>. <source>Genome Biol.</source>
<volume>18</volume>. <pub-id pub-id-type="doi">10.1186/s13059-017-1349-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>LncRNADisease 2.0: an Updated Database of Long Non-coding RNA-Associated Diseases</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D1034</fpage>–<lpage>D1037</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky905</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Lncrnadisease 2.0: an Updated Database of Long Non-coding Rna-Associated Diseases</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D1034</fpage>–<lpage>D1037</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky905</pub-id>
<pub-id pub-id-type="pmid">30285109</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E.</given-names></name><name><surname>Giraldo</surname><given-names>N. A.</given-names></name><name><surname>Lacroix</surname><given-names>L.</given-names></name><name><surname>Buttard</surname><given-names>B.</given-names></name><name><surname>Elarouci</surname><given-names>N.</given-names></name><name><surname>Petitprez</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Estimating the Population Abundance of Tissue-Infiltrating Immune and Stromal Cell Populations Using Gene Expression</article-title>. <source>Genome Biol.</source>
<volume>17</volume>, <fpage>218</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1186/s13059-016-1070-5</pub-id>
<pub-id pub-id-type="pmid">27765066</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Benesty</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Cohen</surname><given-names>I.</given-names></name></person-group> (<year>2009</year>). “<article-title>Pearson Correlation Coefficient</article-title>,” in <source>Noise Reduction in Speech Processing</source> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>), <fpage>1</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-00296-0_5</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhan</surname><given-names>A.</given-names></name><name><surname>Soleimani</surname><given-names>M.</given-names></name><name><surname>Mandal</surname><given-names>S. S.</given-names></name></person-group> (<year>2017</year>). <article-title>Long Noncoding Rna and Cancer: a New Paradigm</article-title>. <source>Cancer Res.</source>
<volume>77</volume>, <fpage>3965</fpage>–<lpage>3981</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.can-16-2634</pub-id>
<pub-id pub-id-type="pmid">28701486</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>LncRNA-FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling</article-title>. <source>Clin. Cancer Res.</source>
<volume>24</volume>, <fpage>4808</fpage>–<lpage>4819</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-17-2967</pub-id>
<pub-id pub-id-type="pmid">29914894</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Torre</surname><given-names>L. A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA: a Cancer J. clinicians</source>
<volume>68</volume>, <fpage>394</fpage>–<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y. G.</given-names></name><name><surname>Satpathy</surname><given-names>A. T.</given-names></name><name><surname>Chang</surname><given-names>H. Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Gene Regulation in the Immune System by Long Noncoding Rnas</article-title>. <source>Nat. Immunol.</source>
<volume>18</volume>, <fpage>962</fpage>–<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3771</pub-id>
<pub-id pub-id-type="pmid">28829444</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Long Non-coding Rna in the Pathogenesis of Cancers</article-title>. <source>Cells</source>
<volume>8</volume>, <fpage>1015</fpage>. <pub-id pub-id-type="doi">10.3390/cells8091015</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>L. M.</given-names></name><name><surname>Zitvogel</surname><given-names>L.</given-names></name><name><surname>Palucka</surname><given-names>A. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?</article-title>
<source>Science</source>
<volume>339</volume>, <fpage>286</fpage>–<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1126/science.1232227</pub-id>
<pub-id pub-id-type="pmid">23329041</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>C. G.</given-names></name><name><surname>Stein</surname><given-names>M. N.</given-names></name></person-group> (<year>2018</year>). <article-title>The Immunobiology of Kidney Cancer</article-title>. <source>J. Clin. Oncol.</source>
<volume>36</volume>, <fpage>3547</fpage>–<lpage>3552</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2018.79.2648</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Non-coding Rnas in Human Disease</article-title>. <source>Nat. Rev. Genet.</source>
<volume>12</volume>, <fpage>861</fpage>–<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3074</pub-id>
<pub-id pub-id-type="pmid">22094949</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Colombet</surname><given-names>M.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Mathers</surname><given-names>C.</given-names></name><name><surname>Parkin</surname><given-names>D. M.</given-names></name><name><surname>Piñeros</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Estimating the Global Cancer Incidence and Mortality in 2018: Globocan Sources and Methods</article-title>. <source>Int. J. Cancer</source>
<volume>144</volume>, <fpage>1941</fpage>–<lpage>1953</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.31937</pub-id>
<pub-id pub-id-type="pmid">30350310</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finotello</surname><given-names>F.</given-names></name><name><surname>Mayer</surname><given-names>C.</given-names></name><name><surname>Plattner</surname><given-names>C.</given-names></name><name><surname>Laschober</surname><given-names>G.</given-names></name><name><surname>Rieder</surname><given-names>D.</given-names></name><name><surname>Hackl</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Molecular and Pharmacological Modulators of the Tumor Immune Contexture Revealed by Deconvolution of Rna-Seq Data</article-title>. <source>Genome Med.</source>
<volume>11</volume>, <fpage>34</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1186/s13073-019-0638-6</pub-id>
<pub-id pub-id-type="pmid">31126321</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname><given-names>A.</given-names></name><name><surname>Diekhans</surname><given-names>M.</given-names></name><name><surname>Jungreis</surname><given-names>I.</given-names></name><name><surname>Lagarde</surname><given-names>J.</given-names></name><name><surname>Loveland</surname><given-names>J. E.</given-names></name><name><surname>Mudge</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Gencode 2021</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume>, <fpage>D916</fpage>–<lpage>D923</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1087</pub-id>
<pub-id pub-id-type="pmid">33270111</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fridman</surname><given-names>W.</given-names></name><name><surname>Galon</surname><given-names>J.</given-names></name><name><surname>Dieunosjean</surname><given-names>M.</given-names></name><name><surname>Cremer</surname><given-names>I.</given-names></name><name><surname>Fisson</surname><given-names>S.</given-names></name><name><surname>Damotte</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2011</year>). “<article-title>Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control</article-title>,” in <source>Cancer Immunology and Immunotherapy</source>. Editor <person-group person-group-type="editor"><name><surname>Dranoff</surname><given-names>G.</given-names></name></person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>), <fpage>1</fpage>–<lpage>24</lpage>. </mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>Comprehensive Analyses of Correlation and Survival Reveal Informative Lncrna Prognostic Signatures in colon Cancer</article-title>. <source>World J. Surg. Oncol.</source>
<volume>19</volume>, <fpage>1</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1186/s12957-021-02196-4</pub-id>
<pub-id pub-id-type="pmid">33388059</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Zhi</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Lnc2Cancer v2.0: Updated Database of Experimentally Supported Long Non-coding RNAs in Human Cancers</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D1028</fpage>–<lpage>D1033</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1096</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharib</surname><given-names>E.</given-names></name><name><surname>Nazemalhosseini-Mojarad</surname><given-names>E.</given-names></name><name><surname>Baghdar</surname><given-names>K.</given-names></name><name><surname>Nayeri</surname><given-names>Z.</given-names></name><name><surname>Sadeghi</surname><given-names>H.</given-names></name><name><surname>Rezasoltani</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Identification of a Stool Long Non-coding Rnas Panel as a Potential Biomarker for Early Detection of Colorectal Cancer</article-title>. <source>J. Clin. Lab. Anal.</source>
<volume>35</volume>, <fpage>e23601</fpage>. <pub-id pub-id-type="doi">10.1002/jcla.23601</pub-id>
<pub-id pub-id-type="pmid">33094859</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharib</surname><given-names>E.</given-names></name><name><surname>Anaraki</surname><given-names>F.</given-names></name><name><surname>Baghdar</surname><given-names>K.</given-names></name><name><surname>Ghavidel</surname><given-names>P.</given-names></name><name><surname>Sadeghi</surname><given-names>H.</given-names></name><name><surname>Nasrabadi</surname><given-names>P. N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Investigating the Diagnostic Performance of Hottip, Pvt1, and uca1 Long Noncoding Rnas as a Predictive Panel for the Screening of Colorectal Cancer Patients with Lymph Node Metastasis</article-title>. <source>J. Cel Biochem</source>
<volume>120</volume>, <fpage>14780</fpage>–<lpage>14790</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.28739</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>E. A.</given-names></name><name><surname>Brown</surname><given-names>C. J.</given-names></name><name><surname>Lam</surname><given-names>W. L.</given-names></name></person-group> (<year>2011</year>). <article-title>The Functional Role of Long Non-coding Rna in Human Carcinomas</article-title>. <source>Mol. Cancer</source>
<volume>10</volume>, <fpage>38</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-10-38</pub-id>
<pub-id pub-id-type="pmid">21489289</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Hoxc11 Positively Regulates the Long Non-coding Rna Hotair and Is Associated with Poor Prognosis in colon Adenocarcinoma</article-title>. <source>Exp. Ther. Med.</source>
<volume>22</volume>, <fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2021.10745</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Coussens</surname><given-names>L. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment</article-title>. <source>Cancer Cell</source>
<volume>21</volume>, <fpage>309</fpage>–<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.022</pub-id>
<pub-id pub-id-type="pmid">22439926</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Høgdall</surname><given-names>D.</given-names></name><name><surname>Lewinska</surname><given-names>M.</given-names></name><name><surname>Andersen</surname><given-names>J. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma</article-title>. <source>Trends Cancer</source>
<volume>4</volume>, <fpage>239</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="pmid">29506673</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Escobar</surname><given-names>T. M.</given-names></name><name><surname>Muljo</surname><given-names>S. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Expression and Regulation of Intergenic Long Noncoding Rnas during T Cell Development and Differentiation</article-title>. <source>Nat. Immunol.</source>
<volume>14</volume>, <fpage>1190</fpage>–<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2712</pub-id>
<pub-id pub-id-type="pmid">24056746</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ouyang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lao</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Nkila Lncrna Promotes Tumor Immune Evasion by Sensitizing T Cells to Activation-Induced Cell Death</article-title>. <source>Nat. Immunol.</source>
<volume>19</volume>, <fpage>1112</fpage>–<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-018-0207-y</pub-id>
<pub-id pub-id-type="pmid">30224822</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakopovic</surname><given-names>M.</given-names></name><name><surname>Bitar</surname><given-names>L.</given-names></name><name><surname>Seiwerth</surname><given-names>F.</given-names></name><name><surname>Marusic</surname><given-names>A.</given-names></name><name><surname>Krpina</surname><given-names>K.</given-names></name><name><surname>Samarzija</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Immunotherapy for Thymoma</article-title>. <source>J. Thorac. Dis.</source>
<volume>12</volume>, <fpage>7635</fpage>–<lpage>7641</lpage>. <pub-id pub-id-type="doi">10.21037/jtd-2019-thym-12</pub-id>
<pub-id pub-id-type="pmid">33447455</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Ji</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The Long Noncoding Rna Lnc-Egfr Stimulates T-Regulatory Cells Differentiation Thus Promoting Hepatocellular Carcinoma Immune Evasion</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>. <pub-id pub-id-type="doi">10.1038/ncomms15129</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>J. A.</given-names></name><name><surname>Fearon</surname><given-names>D. T.</given-names></name></person-group> (<year>2015</year>). <article-title>T Cell Exclusion, Immune Privilege, and the Tumor Microenvironment</article-title>. <source>Science</source>
<volume>348</volume>, <fpage>74</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa6204</pub-id>
<pub-id pub-id-type="pmid">25838376</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalavska</surname><given-names>K.</given-names></name><name><surname>Schmidtova</surname><given-names>S.</given-names></name><name><surname>Chovanec</surname><given-names>M.</given-names></name><name><surname>Mego</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Immunotherapy in Testicular Germ Cell Tumors</article-title>. <source>Front. Oncol.</source>
<volume>10</volume>, <fpage>573977</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.573977</pub-id>
<pub-id pub-id-type="pmid">33072608</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Lied</surname><given-names>A.</given-names></name><name><surname>Kulkarni</surname><given-names>V.</given-names></name><name><surname>Rucevic</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>M. P.</given-names></name><name><surname>Walker-Sperling</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ccr5as Lncrna Variation Differentially Regulates Ccr5, Influencing Hiv Disease Outcome</article-title>. <source>Nat. Immunol.</source>
<volume>20</volume>, <fpage>824</fpage>–<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-019-0406-1</pub-id>
<pub-id pub-id-type="pmid">31209403</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Severson</surname><given-names>E.</given-names></name><name><surname>Pignon</surname><given-names>J. C.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Novak</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy</article-title>. <source>Genome Biol.</source>
<volume>17</volume>. <pub-id pub-id-type="doi">10.1186/s13059-016-1028-7</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>van Breugel</surname><given-names>P. C.</given-names></name><name><surname>Loayza-Puch</surname><given-names>F.</given-names></name><name><surname>Ugalde</surname><given-names>A. P.</given-names></name><name><surname>Korkmaz</surname><given-names>G.</given-names></name><name><surname>Messika-Gold</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Lncrna-ois1 Regulates Dpp4 Activation to Modulate Senescence Induced by Ras</article-title>. <source>Nucleic Acids Res.</source>
<volume>46</volume>, <fpage>4213</fpage>–<lpage>4227</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky087</pub-id>
<pub-id pub-id-type="pmid">29481642</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pan-cancer Characterization of Immune-Related Lncrnas Identifies Potential Oncogenic Biomarkers</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, <fpage>1000</fpage>–<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-14802-2</pub-id>
<pub-id pub-id-type="pmid">32081859</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Lncrna Fezf1-As1 Is Associated with Prognosis in Lung Adenocarcinoma and Promotes Cell Proliferation, Migration, and Invasion</article-title>. <source>Oncol. Res.</source>
<volume>27</volume>, <fpage>39</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.3727/096504018x15199482824130</pub-id>
<pub-id pub-id-type="pmid">29510777</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Lncrna Fezf1-As1 Sponges Mir-34a to Upregulate Notch-1 in Glioblastoma</article-title>. <source>Cancer Manag. Res.</source>
<volume>12</volume>, <fpage>1827</fpage>–<lpage>1833</lpage>. <pub-id pub-id-type="doi">10.2147/cmar.s240531</pub-id>
<pub-id pub-id-type="pmid">32210625</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>K. D.</given-names></name><name><surname>Nogueira</surname><given-names>L.</given-names></name><name><surname>Mariotto</surname><given-names>A. B.</given-names></name><name><surname>Rowland</surname><given-names>J. H.</given-names></name><name><surname>Yabroff</surname><given-names>K. R.</given-names></name><name><surname>Alfano</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Cancer Treatment and Survivorship Statistics, 2019</article-title>. <source>CA A. Cancer J. Clin.</source>
<volume>69</volume>, <fpage>363</fpage>–<lpage>385</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21565</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>K. D.</given-names></name><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Lin</surname><given-names>C. C.</given-names></name><name><surname>Mariotto</surname><given-names>A. B.</given-names></name><name><surname>Kramer</surname><given-names>J. L.</given-names></name><name><surname>Rowland</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Cancer Treatment and Survivorship Statistics, 2016</article-title>. <source>CA: a Cancer J. clinicians</source>
<volume>66</volume>, <fpage>271</fpage>–<lpage>289</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21349</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>L.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name><name><surname>Basu</surname><given-names>U.</given-names></name></person-group> (<year>2020</year>). <article-title>Regulation of Long Non-coding Rnas and Genome Dynamics by the Rna Surveillance Machinery</article-title>. <source>Nat. Rev. Mol. Cel Biol</source>
<volume>21</volume>, <fpage>123</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-019-0209-0</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazemalhosseini-Mojarad</surname><given-names>E.</given-names></name><name><surname>Mohammadpour</surname><given-names>S.</given-names></name><name><surname>Torshizi Esafahani</surname><given-names>A.</given-names></name><name><surname>Gharib</surname><given-names>E.</given-names></name><name><surname>Larki</surname><given-names>P.</given-names></name><name><surname>Moradi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Intratumoral Infiltrating Lymphocytes Correlate with Improved Survival in Colorectal Cancer Patients: Independent of Oncogenetic Features</article-title>. <source>J. Cel Physiol</source>
<volume>234</volume>, <fpage>4768</fpage>–<lpage>4777</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27273</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>P.</given-names></name><name><surname>Jaé</surname><given-names>N.</given-names></name><name><surname>Knau</surname><given-names>A.</given-names></name><name><surname>Glaser</surname><given-names>S. F.</given-names></name><name><surname>Fouani</surname><given-names>Y.</given-names></name><name><surname>Rossbach</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The Lncrna Gata6-As Epigenetically Regulates Endothelial Gene Expression via Interaction with Loxl2</article-title>. <source>Nat. Commun.</source>
<volume>9</volume>. <pub-id pub-id-type="doi">10.1038/s41467-017-02431-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>A. M.</given-names></name><name><surname>Liu</surname><given-names>C. L.</given-names></name><name><surname>Green</surname><given-names>M. R.</given-names></name><name><surname>Gentles</surname><given-names>A. J.</given-names></name><name><surname>Feng</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Robust Enumeration of Cell Subsets from Tissue Expression Profiles</article-title>. <source>Nat. Methods</source>
<volume>12</volume>, <fpage>453</fpage>–<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>
<pub-id pub-id-type="pmid">25822800</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obaid</surname><given-names>M.</given-names></name><name><surname>Udden</surname><given-names>S. M. N.</given-names></name><name><surname>Alluri</surname><given-names>P.</given-names></name><name><surname>Mandal</surname><given-names>S. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Lncrna Hotair Regulates Glucose Transporter Glut1 Expression and Glucose Uptake in Macrophages during Inflammation</article-title>. <source>Sci. Rep.</source>
<volume>11</volume>. <pub-id pub-id-type="doi">10.1038/s41598-020-80291-4</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>J. J.</given-names></name><name><surname>Gadina</surname><given-names>M.</given-names></name><name><surname>Siegel</surname><given-names>R. M.</given-names></name></person-group> (<year>2019</year>). “<article-title>Cytokines and Cytokine Receptors</article-title>,” in <source>Clinical Immunology</source>. Editors <person-group person-group-type="editor"><name><surname>Rich</surname><given-names>R. R.</given-names></name><name><surname>Fleisher</surname><given-names>T. A.</given-names></name><name><surname>Shearer</surname><given-names>W. T.</given-names></name><name><surname>Schroeder</surname><given-names>H. W.</given-names></name><name><surname>Frew</surname><given-names>A. J.</given-names></name><name><surname>Weyand</surname><given-names>C. M.</given-names></name></person-group>. <edition>Fifth edition edn</edition> (<publisher-loc>London</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>127</fpage>–<lpage>155</lpage>. </mixed-citation>
    </ref>
    <ref id="B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paredes</surname><given-names>J.</given-names></name><name><surname>Zabaleta</surname><given-names>J.</given-names></name><name><surname>Garai</surname><given-names>J.</given-names></name><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Imtiaz</surname><given-names>S.</given-names></name><name><surname>Spagnardi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Immune-related Gene Expression and Cytokine Secretion Is Reduced Among African American colon Cancer Patients</article-title>. <source>Front. Oncol.</source>
<volume>10</volume>, <fpage>1498</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.01498</pub-id>
<pub-id pub-id-type="pmid">32983990</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quail</surname><given-names>D. F.</given-names></name><name><surname>Joyce</surname><given-names>J. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Microenvironmental Regulation of Tumor Progression and Metastasis</article-title>. <source>Nat. Med.</source>
<volume>19</volume>, <fpage>1423</fpage>–<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3394</pub-id>
<pub-id pub-id-type="pmid">24202395</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>J. D.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Khavari</surname><given-names>P. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The Functions and Unique Features of Long Intergenic Non-coding Rna</article-title>. <source>Nat. Rev. Mol. Cel Biol</source>
<volume>19</volume>, <fpage>143</fpage>–<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.104</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schott</surname><given-names>M.</given-names></name><name><surname>Seissler</surname><given-names>J.</given-names></name><name><surname>Lettmann</surname><given-names>M.</given-names></name><name><surname>Fouxon</surname><given-names>V.</given-names></name><name><surname>Scherbaum</surname><given-names>W. A.</given-names></name><name><surname>Feldkamp</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Immunotherapy for Medullary Thyroid Carcinoma by Dendritic Cell Vaccination</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>86</volume>, <fpage>4965</fpage>–<lpage>4969</lpage>. <pub-id pub-id-type="doi">10.1210/jcem.86.10.7949</pub-id>
<pub-id pub-id-type="pmid">11600571</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedgwick</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Spearman's Rank Correlation Coefficient</article-title>. <source>BMJ</source>
<volume>349</volume>, <fpage>g7327</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.g7327</pub-id>
<pub-id pub-id-type="pmid">25432873</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Identification and Validation of Immune-Related Lncrna Prognostic Signature for Breast Cancer</article-title>. <source>Genomics</source>
<volume>112</volume>, <fpage>2640</fpage>–<lpage>2646</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygeno.2020.02.015</pub-id>
<pub-id pub-id-type="pmid">32087243</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Miller</surname><given-names>K. D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Cancer Statistics, 2015</article-title>. <source>CA: a Cancer J. clinicians</source>
<volume>65</volume>, <fpage>5</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21254</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spill</surname><given-names>F.</given-names></name><name><surname>Reynolds</surname><given-names>D. S.</given-names></name><name><surname>Kamm</surname><given-names>R. D.</given-names></name><name><surname>Zaman</surname><given-names>M. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Impact of the Physical Microenvironment on Tumor Progression and Metastasis</article-title>. <source>Curr. Opin. Biotechnol.</source>
<volume>40</volume>, <fpage>41</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2016.02.007</pub-id>
<pub-id pub-id-type="pmid">26938687</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Bao</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Hou</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Identification of Tumor Immune Infiltration-Associated Lncrnas for Improving Prognosis and Immunotherapy Response of Patients with Non-small Cell Lung Cancer</article-title>. <source>J. Immunother. Cancer</source>
<volume>8</volume>, <fpage>110</fpage>. <pub-id pub-id-type="doi">10.1136/jitc-2019-000110</pub-id>
</mixed-citation>
    </ref>
    <ref id="B56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topham</surname><given-names>N. J.</given-names></name><name><surname>Hewitt</surname><given-names>E. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Natural Killer Cell Cytotoxicity: How Do They Pull the Trigger?</article-title>
<source>Immunology</source>
<volume>128</volume>, <fpage>7</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2009.03123.x</pub-id>
<pub-id pub-id-type="pmid">19689731</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Harten</surname><given-names>R.</given-names></name><name><surname>Van Woudenbergh</surname><given-names>E.</given-names></name><name><surname>Van Dijk</surname><given-names>A.</given-names></name><name><surname>Haagsman</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Cathelicidins: Immunomodulatory Antimicrobials</article-title>. <source>Vaccines</source>
<volume>6</volume>, <fpage>63</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines6030063</pub-id>
</mixed-citation>
    </ref>
    <ref id="B58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname><given-names>J. M.</given-names></name><name><surname>Van der Veen</surname><given-names>A. G.</given-names></name><name><surname>Ploegh</surname><given-names>H. L.</given-names></name></person-group> (<year>2008</year>). <article-title>The Known Unknowns of Antigen Processing and Presentation</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>8</volume>, <fpage>607</fpage>–<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1038/nri2368</pub-id>
<pub-id pub-id-type="pmid">18641646</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K. C.</given-names></name><name><surname>Chang</surname><given-names>H. Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular Mechanisms of Long Noncoding Rnas</article-title>. <source>Mol. Cel.</source>
<volume>43</volume>, <fpage>904</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.018</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.-D.</given-names></name><name><surname>Sun</surname><given-names>X.-J.</given-names></name><name><surname>Yin</surname><given-names>J.-J.</given-names></name><name><surname>Yin</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Nie</surname><given-names>Z.-Q.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Long Non-coding Rna Fezf1-As1 Promotes Cell Invasion and Epithelial-Mesenchymal Transition through Jak2/stat3 Signaling Pathway in Human Hepatocellular Carcinoma</article-title>. <source>Biomed. Pharmacother.</source>
<volume>106</volume>, <fpage>134</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.05.116</pub-id>
<pub-id pub-id-type="pmid">29957463</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Lncrna: a Link between Rna and Cancer</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1839</volume>, <fpage>1097</fpage>–<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.08.012</pub-id>
<pub-id pub-id-type="pmid">25159663</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.-C.</given-names></name><name><surname>Sun</surname><given-names>C.-K.</given-names></name><name><surname>Chen</surname><given-names>Q.-M.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of the Tumor Microenvironment in Tumor Progression and the Clinical Applications (Review)</article-title>. <source>Oncol. Rep.</source>
<volume>35</volume>, <fpage>2499</fpage>–<lpage>2515</lpage>. <pub-id pub-id-type="doi">10.3892/or.2016.4660</pub-id>
<pub-id pub-id-type="pmid">26986034</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H. H.</given-names></name><name><surname>Li</surname><given-names>A. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Long Non-coding Rna Fezf1-As1 Is Up-Regulated and Associated with Poor Prognosis in Patients with Cervical Cancer</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>22</volume>, <fpage>3357</fpage>–<lpage>3362</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201806_15156</pub-id>
<pub-id pub-id-type="pmid">29917186</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Comprehensive Characterization of Lncrna-Mrna Related Cerna Network across 12 Major Cancers</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>64148</fpage>–<lpage>64167</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.11637</pub-id>
<pub-id pub-id-type="pmid">27580177</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Mo</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Immune‐related Long Noncoding RNA Signature for Predicting Survival and Immune Checkpoint Blockade in Hepatocellular Carcinoma</article-title>. <source>J. Cel Physiol</source>
<volume>235</volume>, <fpage>9304</fpage>–<lpage>9316</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.29730</pub-id>
</mixed-citation>
    </ref>
    <ref id="B66">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>LncTarD: a Manually-Curated Database of Experimentally-Supported Functional lncRNA-Target Regulations in Human Diseases</article-title>. <source>Nucleic Acids Res.</source>
<volume>48</volume>, <fpage>D118</fpage>–<lpage>D126</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz985</pub-id>
<pub-id pub-id-type="pmid">31713618</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Fang</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Noncode 2016: an Informative and Valuable Data Source of Long Non-coding Rnas</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>D203</fpage>–<lpage>D208</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1252</pub-id>
<pub-id pub-id-type="pmid">26586799</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Emerging Roles of Long Non-coding Rnas in the Tumor Microenvironment</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>16</volume>, <fpage>2094</fpage>–<lpage>2103</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.44420</pub-id>
<pub-id pub-id-type="pmid">32549757</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Pan</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Integrated Bioinformatics Analysis Revealing Independent Prognostic Long Non-coding RNAs DNAH17-AS1 and RP11-400N13.2 and Their Potential Oncogenic Roles in Colorectal Cancer</article-title>. <source>Oncol. Lett.</source>
<volume>18</volume>, <fpage>3705</fpage>–<lpage>3715</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10730</pub-id>
<pub-id pub-id-type="pmid">31516583</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L. F.</given-names></name><name><surname>Song</surname><given-names>L. D.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Zhan</surname><given-names>J. F.</given-names></name></person-group> (<year>2019</year>). <article-title>Highly Expressed Long Non-coding Rna Fezf1-As1 Promotes Cells Proliferation and Metastasis through Notch Signaling in Prostate Cancer</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>23</volume>, <fpage>5122</fpage>–<lpage>5132</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201906_18176</pub-id>
<pub-id pub-id-type="pmid">31298365</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
